EPISODE · Apr 16, 2026 · 1 MIN
Phase 2b Biomarker Analysis: BCMA CAR-T in Myasthenia Gravis
from TheBrief.Health · host TheBrief.Health
BCMA-directed CAR-T therapy shows promise in myasthenia gravis by selectively targeting plasma cells, improving outcomes, and prompting biomarker-guided care, outpatient delivery models, and health system adaptation.
What this episode covers
BCMA-directed CAR-T therapy shows promise in myasthenia gravis by selectively targeting plasma cells, improving outcomes, and prompting biomarker-guided care, outpatient delivery models, and health system adaptation.
NOW PLAYING
Phase 2b Biomarker Analysis: BCMA CAR-T in Myasthenia Gravis
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m